Sirexatamab
司瑞妥单抗
Report date: 2024/02/05 16:46:27
Base Information
Drug NameSirexatamab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[18]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[4]
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A
Develop Information
Active CompaniesLeap Therapeutics IncBeOne Medicines LtdThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesJohannes Gutenberg-University Mainz
Active Indications
Inactive Indications +[15]
Other Information
ATC CodeN/A
Related LinksN/A